

# Cumulative Index 1988

## Volume 11

<b>March</b>	<b>PSYCHOSIS AND DEPRESSION IN THE ELDERLY</b> , pages 1-286
<b>June</b>	<b>BIOLOGIC SYSTEMS: THEIR RELATIONSHIP TO ANXIETY DISORDERS</b> , pages 287-476
<b>September</b>	<b>HEMISPHERIC SPECIALIZATION</b> , pages 287-497*
<b>December</b>	<b>THE VIOLENT PATIENT</b> , pages 499-698

\*Page numbers in index denoted by asterisk appear in September issue

*Note:* Page numbers of issue and article titles appear in **boldface** type.

- Affect**, 135-136  
 definition of, 288, 289  
 handwriting expression of, 331-338\*  
 hemispheric specialization and, 289\*  
 post-traumatic, 480
- Affective disorders**, alexithymia and, 287-290, 476, 485-487\*  
 creativity correlated to, 388\*  
 hemispheric brain dysfunction and, 368-369\*  
 late-onset, 17-18  
 brain disease/injury and, 20, 22  
 deafness and, 19  
 epidemiology of, 85-87  
 gender correlation to, 24  
 genetic factors of, 18-19  
 historical review of, 17-18  
 physical diseases and, 22  
 premorbid personality and, 23  
 sensory impairment and, 19-20
- Aged patients**. See *Elderly patients*.
- Aging**, body composition changes with, 237-238  
 cardiovascular changes with, 236  
 central nervous system changes with, 236  
 dementia and, 107  
 depression and, 107  
 dopaminergic transmission with, 63-65  
 gastrointestinal tract changes with, 236  
 hepatic changes with, 237  
 motor system changes with, 62-63  
 movement disorders associated with, 62-66  
 musculoskeletal changes with, 62  
 nervous system changes with, 62-63  
 neurochemical changes in, 22-23  
 pharmacokinetic changes with, 217, 236-238  
 physiologic changes with, 236-238  
 postural changes with, 63  
 renal changes with, 236-237
- Aggression**. See *Violent behavior*.
- Agnosia**, interoceptive, 385\*
- Agoraphobia**, depression concurrent with, 445  
 ear disease and, 361  
 panic disorder concurrent with, 445  
 urinary free cortisol abnormalities and, 339-345  
 vestibular abnormalities and, 361, 363, 366
- Akathisia**, neuroleptic-induced, 68, 203
- Alcoholism**, anxiety disorders and, 289, 291-292  
 panic disorder and, 465  
 prevalence of, 291

**Alcoholism (Continued)**

- violent behavior correlated to, 504-505, 561
  - child abuse and, 596
  - legal implications of, 674
  - spouse abuse and, 620
- Alexithymia, affective disturbance and, 287-290, 476, 485-487\*
  - brain damage/dysfunction correlated to, 289-290\*
    - arcuate fasciculus, 325\*
    - corpus callosum, 317-338\*
  - cognitive development and, 337\*
  - cognitive disturbances and, 475-476, 485-487\*
  - conduction aphasia and, 325\*
  - construct definition for, 352-353\*
  - creativity in relation to, 290-292, 306\*
    - definition of, 287, 288\*
  - EEG analysis of, 305-306, 317-327
    - alpha-band intensity in, 318, 322-323
    - cross-spectral alpha-band coherences in, 323-324\*
    - expressiveness measurements for, 319\*
    - film stimulus for, 318-319\*
    - intrahemispheric coherences in, 318\*
    - method of, 321-322\*
    - recording procedures for, 321\*
  - etiology of, 289-291\*
  - graphologic signs of, 331-338\*
    - cognitive development and, 337\*
    - form level index of, 333-336\*
    - intercoder reliability analysis of, 333-334\*
    - item analysis of, 334\*
    - method of analysis of, 332-333\*
    - qualitative analysis of, 336-337
  - hemispheric specialization and, 287, 289-292\*
  - interhemispheric communication and, 325-326, 331\*
  - measurement of, 351-363\*
    - Alexithymia Provoked Response Questionnaire, 354\*
    - Beth Israel Hospital Psychomotor Questionnaire, 353-354\*
    - computerized axial tomography, 351-352\*
    - construct definition for, 352-353\*
    - magnetic resonance imaging, 352\*
    - MMPI Alexithymia Scale, 355-356\*
    - Objectively Scored Archetypal Test, 359-360\*
    - observer-rated questionnaire, 353-354\*
    - Physiognomic Cue Test, 363\*
    - positron emission tomography, 352\*
    - projective techniques of, 358-360\*
    - Rorschach Test, 358\*
    - Schalling-Sifneos Personality Scale, 354-355\*
    - self-report scale, 354-358\*
    - Short Imaginal Processes Inventory, 363\*
    - single photon emission tomography, 352\*
    - Thematic Apperception Test, 358\*
    - Toronto Alexithymia Scale, 356-358, 360-363
    - Verbalizer-Visualizer questionnaire, 363\*
  - neuroanatomic correlation to, 289-290, 317-338\*
  - neurophysiologic mechanisms of, 318, 325-326\*
  - pathologic conditions associated with, 287-288, 289\*
  - primary, 289-290\*
  - psychodynamic factors predisposing to, 290\*
  - secondary, 290-291\*
  - signs and symptoms of, 346\*
  - sociocultural factors predisposing to, 290\*
  - solace in, absence of, 470\*
  - therapeutic interventions for, 291
  - traumatic events predisposing to, 290, 480-482\*
  - wish-fulfillment fantasy in, blocking of, 476\*
- Alexithymia Provoked Response Questionnaire, 354\*
- Alzheimer's disease, dementia of, 195
  - depression and, 105, 107
  - psychosis and, 20-21, 49
  - movement disorders and, 73-74
  - neuroimaging studies of, 36, 41-42
- Amitriptyline, geriatric drug therapy of, 217-218
  - cardiovascular effects of, 220
  - efficacy of, 223, 226
  - pharmacokinetics of, 217-218
- Amphetamines, geriatric drug therapy of, 228
  - psychiatric side effects of, 188
  - violent behavior therapy with, 559-561
- Amygdaloid complex, visceral emotions and, 288
- Analgesics, mechanisms of action of, 171
  - psychiatric side effects of, 171-174
- Androgens, mechanism of action of, 179
  - psychiatric side effects of, 179, 180
- Anticonvulsants, mechanism of action of, 177-178
  - psychiatric side effects of, 178
  - violent behavior therapy and, 554-555
- Antidepressants, geriatric drug therapy of, 215-233
  - cognitive impairment issues in study of, 217
  - diagnostic issues in studies of, 216
  - efficacy of, 221-226

- monoamine oxidase inhibitors. See *Monoamine oxidase inhibitors, geriatric drug therapy of.*
- pharmacokinetics of, 217-218
- plasma levels of, 218-219
- psychostimulants and, 228-229
- side effects of, 220-221
- tricyclic antidepressants and. See *Tricyclic antidepressants, geriatric drug therapy of.*
- mechanism of action of, 175
- psychiatric side effects of, 175-177
- violent behavior therapy and, 561
- Antihistamines, mechanism of action, 168
- psychiatric side effects of, 168-170
- Antihypertensives, mechanism of action of, 181-182
- psychiatric side effects of, 182-186
- TCA drug interaction with, 259-260
- Anti-inflammatory drugs, lithium interaction with, 268
- mechanisms of action of, 171
- psychiatric side effects of, 171-174
- Antineoplastic agents, mechanism of action of, 173
- psychiatric side effects of, 175, 176
- Anxiety, autonomic responses and, 375-378
- brain lesions and, 300-302
- components of, 296-298
- definition of, 287, 295-298
- electrical stimulation of brain and, 300-302
- evaluative aspects of, 296, 297-298
- expression of, 296-297
- functional brain mapping studies of, 302-304
- neuroanatomic studies of, 295-307
- animal vs human, 298
- electrical stimulation, 300-302
- functional brain mapping, 302-304
- selective lesion, 300-302
- peripheral nervous system and, 375-378
- subjective experience of, 296
- Anxiety disorders, alcoholism and, 289, 291-292
- biologic systems in relation to, 463-472
- diagnostic terminology and, 463-464
- hyperventilation and, 467-468
- muscular contractility and, 467-468
- problems of association of, 468-470
- selection bias in studies of, 466
- types of tests of, 464-465
- variable expressivity of psychiatric illness and, 465-466
- chest pain and, 387-397
- angiographically normal coronary arteries with, 390-391
- atypical or nonanginal, 391-393
- drug therapy for, 393-395
- child abuse as cause of, 600
- corticotropin-releasing hormone in, 327-334
- definition of anxiety and, 287, 295-298
- depression and, 288-291, 441-461
- diabetes mellitus and. See *Diabetes mellitus, anxiety disorders and.*
- diagnostic terminology of, 463-464
- diurnal variation of, 448-449
- gastrointestinal illness and. See *Gastrointestinal system, anxiety and.*
- hypothalamic-pituitary-adrenal axis activity and, 335-348
- immune system and, 349-360
- medical practice detection of, 466-467
- monoamine receptor systems and, 309-326
- dopaminergic, 310
- GABAergic, 310-311
- histaminergic, 310
- noradrenergic, 310-316, 318-322, 452-454
- serotonergic, 310-311, 316-322, 454-455
- mortality and, 433-440
- cardiovascular, 435-438
- suicidal, 433-435
- peripheral sympathetic nervous system and, 375-386, 469
- blood-injury phobia and, 378-379
- generalized anxiety disorder and, 380-381
- normal anxiety and, 377-378
- obsessive-compulsive disorder and, 381-382
- panic disorder and, 379-380
- pathologic anxiety and, 378-382
- post-traumatic stress disorder and, 379
- simple phobia and, 378
- social phobia and, 379
- prevalence of, 291
- psychiatric illnesses in relation to, 287-293
- anxiety disorder secondary to psychiatric syndromes and, 289-290
- familial interrelationships of, 290-291
- primary-secondary distinction of, 288
- psychiatric syndromes secondary to anxiety disorder and, 288-289
- schizophrenia and, 289
- variable expressivity of, 465-466
- vestibular system and, 361-374
- historical background of, 361-362
- panic disorder and. See *Vestibular system, panic disorder and dysfunction of.*
- symptoms relating, 362
- vertigo and, 361-362, 366

- Anxiolytics, benzodiazepine. See *Benzodiazepines*.
- geriatric drug therapy of, 92
- movement disorders induced by, 75
- psychiatric side effects of, 183, 187
- mechanism of action of, 183
- violent behavior therapy with, 552-553, 557-558
- Arcuate fasciculus, conduction aphasia and, 325
- Baclofen, psychiatric side effects of, 189
- violent behavior therapy and, 561
- Barbiturates, neuroleptic drug interactions with, 244
- TCA drug interactions with, 262
- violent behavior therapy and, 552, 554
- Bereavement, immune system response to, 350-352
- Behavioral therapy, for dementia of elderly, 208
- for violent behavior, 569-580
- acceleration techniques of, 572-574
- administrative issues of, 577-578
- behavioral analyst in, role of, 577-578
- contingent restraint in, 576-577
- deceleration techniques of, 574-577
- differential reinforcement schedules in, 573-574
- efficacy of, 571
- institutional review of, 578
- overcorrection in, 576
- planning process for, patient participation in, 577
- positive programming in, 572-574
- program components of, 570-572
- response cost procedures in, 574
- social extinction in, 575
- social skills training in, 573
- stimuli modification in, 571-572
- target behaviors in, 570-571
- theoretical aspects of, 570
- time out from reinforcement in, 575-576
- token economies and level systems in, 572-573
- unit program manual for, 578
- Benzodiazepines, dementia of elderly and, 206
- mechanism of action of, 183
- movement disorders induced by, 75
- psychiatric side effects of, 183, 187
- violent behavior therapy and, 552-553, 557-558
- Beta-adrenergic blockers, dementia of elderly and, 206
- Beth Israel Hospital Psychosomatic Questionnaire, 303-304, 353-354
- Binswanger's disease, 37
- Bipolar disorder, late-onset, 117-131
- anger in, 119
- circumstantiality in, 119
- classification systems for, 84
- clinical course of, 127
- confusional states of, 119-120
- delusional, 118-119
- depression in, 119
- diagnosis of, 126
- differential diagnosis of, 126-127
- epidemiology of, 85-87, 117-118, 121-124
- etiology of, 124-126
- family history as factor in, 124
- flight of ideas in, 118, 119
- hyperactivity of, 118
- insomnia of, 118
- irritability of, 119
- neuropsychological studies of, 51
- pseudodementia of, 120
- secondary mania of, 120-121
- sex differences of, 124
- signs and symptoms of, 118-121
- treatment of, 127-128
- Brain, anxiety correlations with, electrical stimulation and, 300-302
- functional brain mapping studies and, 302-304
- surgical lesions and, 300-302
- positron emission tomography of, 302, 468-469
- Brain diseases and injury, late-onset depression and, 107-109, 133-134
- late-onset psychosis and, 20-22
- Alzheimer's disease and, 41-42
- degenerative dementia and, 41-42
- diagnosis of, 43-44
- historical review of, 35-37
- medical approach to, 43-44
- metabolic encephalopathy and, 40-41
- minimal pathology and, 42-43
- neuroimaging studies of, 38-43
- silent vascular disease and, 38-40
- tumors and, 42
- mass lesions and. See *Intracranial mass lesions*.
- mood disorders and, 133-136
- right vs left hemispheric injury, effect of, 136
- stroke and. See *Stroke*.
- tumors and. See *Brain tumors*.
- violent behavior correlation to, 503, 560
- Brain tumors, differential diagnosis of, 154, 155
- neurologic symptoms associated with, 160-161
- psychiatric symptoms associated with, 151-163
- catatonia and, 158

- delusions and, 157
  - depressive, 158-159
  - etiology of, 159-160
  - hallucinations and, 157-158
  - mania and, 159
  - personality change and, 159
  - postsurgical, 162
  - prevalence of, 152-154, 156-157
  - schizophrenia-like psychosis and, 157
- Calcium-channel blockers, dementia of elderly and, 206
- lithium interaction with, 269
- Capgras syndrome, brain injury and, 36
- stroke-induced, 143-144
- Carbamazepine, geriatric drug therapy of, bipolar disorder and, 127
- dementia and, 206-207
- drug interactions with, 242-243, 269
- lithium interactions with, 269
- movement disorders induced by, 76
- neuroleptic drug interactions with, 242-243
- violent behavior therapy and, 554-555, 559
- Cardiac drugs, mechanism of action of, 179
- psychiatric side effects of, 180-181, 184-186
- Cardiovascular disease, chest pain of. See *Chest pain*.
- panic disorders and, chest pain and, 390-395
- mortality rates and, 435-439
- Catatonia, brain tumor-induced, 158
- late-onset, 74
- neuroleptic-induced, 68
- schizophrenia, 74
- Cerebral hemispheres, asymmetry of, 296\*
- commensal functioning of, 401, 404\*
- commissurotomy effect on, 296-297, 386-387\*
- complementary relationship between, 400, 401, 404-405\*
- concordant relationship between, 404\*
- corpus callosum interconnection of, 296-297\*
- callosotomy of, effect of\* enlargement of, effect of, 407\*
- cortical spreading depression, effect of, 297-298\*
- dialectic operations and, 399-401\*
- dream imagery and, 406-407\*\*
- drug effects on, 342-347\*
- duplicative functions of, 400, 401, 405\*
- dysynchrony of, 402\*
- facial recognition and, 386\*
- generative mechanism of self and, 386\*
- growth and development of, 403\*
- homospatial thinking and, 400, 443-458\*
- image coding and, 386\*
- independent sensory functioning of, 295-296, 405\*
- Janusian thinking and, 389-390, 400\*
- language/linguistic processing areas of, 403, 461\*
- left side, role of, 385-386, 403, 418-422\*
- logical descriptive analysis, area of, 385\*
- mental function correlated to, 402-406\*
- modes of thought and, 377\*
- motor sequencing, area of, 403\*
- oppositional relationship between, 401, 404\*
- parallel processing of information in, 403-404\*
- perceptual judgments, area of, 401, 404\*
- propositional thinking and, 401\*
- right side, role of, 385-386, 403, 417-418\*
- spatial processing, area of, 386\*
- specialization of. See *Hemispheric specialization*.\*
- speech, area of, 403\*
- transfer of information between, 296-297\*
- Cerebrovascular accident. See *Stroke*:
- Chest pain, angiographically normal coronary arteries and, 387-389
- etiology of, 389
- panic disorder and, 390-391
- prevalence of, 387-388
- prognosis for, 388-389
- panic disorder and, 390-395
- angiographically normal coronary arteries and, 390-391
- atypical or nonanginal pain and, 391-393
- drug therapy for, 396-395
- Child abuse, 591-610
- academic performance and, changes in, 602
- acute anxiety state from, 600
- case studies of, 621-622
- central nervous system impairment from, 603-604
- cognitive impairment from, 603
- defense mechanisms to, 602
- depression from, 601-602
- developmental impairment from, 603
- hypersexuality from, 604-605
- impulse control impairment from, 604
- incidence of, 591-592, 620-621
- intervention of, principles of, 606
- mistrust due to, 601
- paranoid reaction from, 601
- parent-child interaction and, 594-595
- parent profiles in, abuse victim history and, 592-593, 596
- alcohol abuse and, 596
- cognitive impairment and, 594

Child abuse (*Continued*)

- parent profiles in, deprivation/neglect history and, 592-593, 596
- domineering and tyrannical personality and, 596
- environmental stress and, 593
- father-specific, 596-597
- low self-esteem and, 593
- mother-specific, 597-598
- physical isolation and, 597
- physical vs sexual abuse and, 599-600
- psychopathology history and, 593-594
- sexual deviant behavior and, 597
- social isolation and, 593, 597
- physical abuse, definition of, 591
- parent profiles for, 592-595, 599-600
- psychodynamics of, 595-596
- sexual abuse vs, 592, 599-600
- post-traumatic stress disorder from, 602-603
- psychological impairment from, 600
- self-image effect of, 601
- sexual abuse, definition of, 591, 630
- family dynamics of, 598
- male victims of, 599
- parent profiles for, 599-600
- physical abuse vs, 592, 599-600
- risk factors predisposing to, 631
- sexual behavior, effect on, 605
- signs and symptoms of, 621
- suicidal behavior due to, 601-602
- traumatic elements of, 605-606
- traumatic reaction to, 600
- Chlorpromazine, extrapyramidal side effects of, 67
- violent behavior therapy and, 551, 552
- Chorea, senile, 66
- Cognition, alexithymia and, 337, 475, 485-487\*
  - corpus callosum development and, 408\*
  - creativity and, 345, 391-393\*
  - Janusian thinking and, 389\*
  - neuroanatomic correlation to, 384-385\*
  - post-traumatic, 480-482\*
- Computerized tomography, intracranial mass lesion, 161
- late-onset psychosis, 36, 37
- degenerative dementia and, 41-42
- metabolic encephalopathy and, 41
- silent vascular disease and, 38, 40
- tumors and, 42
- Conduction aphasia, 325
- Corpus callosum, cognitive development and, 408\*
  - creativity and. See *Creativity, corpus callosum in, role of.*
  - demyelination/myelination of, effect of, 347, 408\*
  - drug effects on, 344-345\*
  - dysfunctional, 295-296, 306\*

- EEG analysis of, 317-327\*
  - graphologic analysis of, 331-338\*
  - mental illness and, 403\*
  - schizophrenia and, 407\*
- emotional development and, 408\*
- function of, 295-296\*
- growth and development of, 406, 408\*
- interhemispheric transfer of information via, 296-297\*
- mentation and, 295-296\*
- repression and, 408\*
- Cortical spreading depression, 297-298
- Corticotropin-releasing hormone, alprazolam effect on, 330
- anxiety disorders and, 327-334
- depression and, 331
- historical background on investigation of, 328-330
- hypothalamic-pituitary-adrenal axis and, 329
- panic disorder and, 330-332
- stress-mediated responses and, 327
- Cortisol, panic disorder and, 337-346
- stress and, 335-337
- Creativity, affective disorders and, 388\*
- alexithymia in relation to, 290-292, 306\*
- cognitive style correlated to, 345, 391-393\*
- commensal functioning of cerebral hemispheres for, 401
- corpus callosum in, role of, 293-299, 303\*
- callosotomy effect on, 295-296, 304, 306, 313\*
- interhemispheric transfer of information, 296-297\*
- symbollexia and, 303, 307-309\*
- cortical spreading depression and, 297-298\*
- cycles of, 422-425\*
- definition of, 444\*
- depression and, 391\*
- drug effects on, 339-348\*
  - conditioning and, 342\*
  - corpus callosum dysfunction and, 344-345\*
  - demyelination and, 346-347\*
  - EEG studies of, 341-342\*
  - external and internal cues contributing to, 342-343\*
  - functional commissurotomy and, 346\*
  - future research on, 344-347\*
  - hemispheric specialization and, 342, 344-347\*
  - historical perspective of studies of, 341-342\*
  - interhemispheric connection and, 344-346\*
- EEG analysis of, 305-306\*
  - drug effects and, 341-342\*
  - hemispheric bisociation and, 308\*

- ego autonomy and, 384-388\*  
 growth and development of, 475-488\*  
 hemispheric specialization and, 298, 303-313, 374-375\*  
 artist vs businessman case study of, 420-422\*  
 cyclical stages and, 422-424\*  
 deranged bisociation and, 309-313\*  
 dialectic operations and, 416\*  
 EEG analysis of, 305-306, 308\*  
 global-level items analysis of, 305\*  
 Gottschalk-Gleser-level items analysis of, 305, 308\*  
 historical perspective of, 427\*  
 left side, 418-422\*  
 lexical-level items analysis of, 304-306\*  
 predictor models of, 416-417\*  
 right side, 417-418\*  
 sentential level items analysis of, 305, 306\*  
 stimulation of creativity and, 427-428\*  
 homospacial process and, 443-458\*  
 inner vision process technique for stimulation of, 427-440\*  
 biofeedback in, 431\*  
 exercises for, 432-434\*  
 fantasy and playfulness suggestion in, 431, 432\*  
 hemispheric specialization, implications of, 427-428\*  
 imagery in, role of, 429-434\*  
 interhemispheric communication in, 430\*  
 mechanism of, 428\*  
 method of study of, 430-434\*  
 psychotherapists as participants in study of, 430-431, 437-439\*  
 relaxation in, 431\*  
 symbollexia in, role of, 430\*  
 value of, 429\*  
 writers as participants in study of, 430-431, 434-436\*  
 interhemispheric communication in, role of, 306\*  
 drug effects and, 344-346\*  
 stimulation of creativity and, 430\*  
 lack of, causes for, 298-299\*  
 neuroanatomic correlation to, 374-375\*  
 neuropsychology of, 383-394\*  
 obsessive-compulsive personality and, 391-392\*  
 origins of, 475-488\*  
 personality types correlated to, 391-393, 443\*  
 psychoanalytic rationale for, 479-480, 483-485\*  
 psychopathology and, 387-391\*  
 psychosis and, 390\*  
 schizophrenia and, 389-391\*  
 self-regulation and, 477-479\*  
 significance of, 296\*  
 stages of, 293-295\*  
 stimulation of, 427-440\*  
 transitional phenomenon and, 482-483\*  
 traumatization and, 479-482\*  
 cognitive impairments with, 480-482\*  
 infantile psychic, 479-480\*  
 Crohn's disease, anxiety and, 411-412\*
- Degenerative dementia, Alzheimer's disease. See *Alzheimer's disease*.  
 late-onset psychosis and, 36-37  
 neuroimaging of, 41-42  
 neuropsychologic studies of, 48-49  
 Demented elderly, age-related changes and, 107  
 Alzheimer's disease and. See *Alzheimer's disease*.  
 behavioral and psychotic symptoms of, 195-213  
 agitation and, 196  
 behavioral therapy for, 208  
 benzodiazepines for, 206  
 beta-blockers for, 206  
 calcium-channel blockers for, 206  
 carbamazepine for, 206-207  
 electroconvulsive therapy for, 207  
 features associated with, 197-199  
 lithium for, 207  
 neuroleptics for, 197-206, 208-209  
 psychosocial therapy for, 208  
 psychotherapy for, 208  
 trazodone for, 207  
 neuroimaging studies of, 36-37  
 neuropsychologic studies of, 48-49  
 prevalence of, 195  
 Dementia, degenerative. See *Degenerative dementia*.  
 geriatric. See *Demented elderly*.  
 multi-infarct. See *Multi-infarct dementia*.  
 pseudodementia and. See *Pseudodementia*.  
 Depression, agoraphobia concurrent with, 445  
 anxiety disorders and, 288-291  
 biologic markers for, 449-457  
 child abuse as cause of, 601-602  
 classification of, 84  
 clonidine studies of, 313  
 corticotropin-releasing hormone and, 331  
 creativity correlated to, 391\*  
 definition of, 85-86  
 dementia and, 53  
 diabetes mellitus and, 423  
 diagnosis of, 84-85  
 diurnal variation of, 448-449  
 hemispheric brain dysfunction and, 368-369\*

## Depression (Continued)

- hypothalamic-pituitary-adrenal axis in, 449-450
- hypothalamic-pituitary-thyroid axis in, 450-452
- immune system response to, 352-353
- late-onset, 83-115
  - age-related changes and, 107
  - Alzheimer's disease and, 105, 107
  - antidepressants for. See *Antidepressants, geriatric drug therapy of*.
  - anxiolytics for. See *Anxiolytics, geriatric drug therapy of*.
  - brain abnormalities and, 21-22, 107-109
  - case example of, 93-94
  - clinical course of, 91, 102-103
  - cognitive impairment and, 104-105, 217
  - delusional, 91
  - dementia disorders associated with, 104-107
  - diagnosis of, 216
  - differential diagnosis of, 109-110
  - drug-induced. See *Drug-induced psychiatric disorders*.
  - ECT for, 92, 207
  - epidemiology of, 83, 85-87, 137
  - etiology of, 87-88
  - genetics of, 18-19
  - involuntary melancholia and, 17-18
  - masked symptoms of, 89-90
  - movement disorders and, 74-75
  - multi-infarct dementia and, 105
  - neurochemical changes of aging and, 22, 107-109
  - neuropsychological studies of, 51-53
  - parkinsonism and, 22, 74-75
  - pathology of, 87-88
  - physical illnesses associated with, 22, 103-104, 137
  - pseudodementia of, 90-91
  - signs and symptoms of, 88-91, 102-103
  - social factors contributing to, 26
  - stroke and. See *Stroke, depression associated with*.
  - treatment of, 91-92
- noradrenergic system in, 452-454
- obsessive-compulsive disorder concurrent with, 448
- panic disorders and. See *Panic disorders, depression and*.
- phobia concurrent with, 445-447
- prevalence of, 291
- psychiatric illnesses in relation to, 288
- rape trauma as cause of, 639
- schizophrenia and, 288
- serotonergic system in, 454-455
- sleep and sleep deprivation effects on, 455
- urinary free cortisol abnormalities and, 339-345
- Desipramine, geriatric drug therapy of, 218
  - cardiovascular effects of, 221
  - pharmacokinetics of, 218
  - plasma levels of, 218-219
- Diabetes mellitus, 419-432
  - anxiety disorders and, 419-429
    - diagnosis of, 423-427
    - generalized anxiety disorder, 427-429
    - historical background of, 419
    - physiologic considerations of, 420-422
    - prevalence of, 423-427
    - prognosis for, 428-429
    - sex and age distribution for, 424
    - treatment of, 429
  - depression and, 423
  - psychologic problems from glucose dysregulation and, 421-422
  - stress effects on, 420-421
- Dizziness, functional, 367-368
  - hyperventilation and, 367-369
  - panic disorder and, 362, 368
  - psychogenic, 367-368
- Drug abuse, violent behavior correlated to, 504-505, 561, 674
- Drug-induced movement disorders, geriatric, 67-70
  - acute dystonic reactions and, 67-68
  - akathisia and, 68
  - benzodiazepines and, 75
  - carbamazepine and, 76
  - catatonia and, 68
  - lithium and, 75-76
  - neuroleptics and, 66-70
  - parkinsonism and, 68
  - tardive dyskinesia and, 61, 67, 69-70
- Drug-induced psychiatric disorders, geriatric, 167-193
  - amphetamines and, 188
  - analgesics and, 171-174
  - androgens and, 179-180
  - anticonvulsants and, 177-178
  - antidepressants and, 175-177
  - antihistamines and, 168-170
  - antihypertensives and, 181-186
  - anti-inflammatory agents and, 171-174
  - antineoplastic agents and, 173-176
  - anxiolytics and, 183-187
  - baclofen and, 189
  - benzodiazepines and, 183-187
  - cardiac drugs and, 179-181, 184-186
  - metrizamide and, 189
  - parkinsonism drug therapy and, 169-172
  - review of literature of, 168
  - sedatives/hypnotics and, 183-187
  - steroids and, 179-180
  - stimulants and, 188
  - thyroid replacement therapy and, 188-189
  - tuberculosis drug therapy and, 173, 175



- Drug interactions, geriatric psychotropic drug therapy, 235-277
- antacid-neuroleptic interactions, 245
  - antiarrhythmic agent-TCA interaction, 260
  - anticholinergic agent-neuroleptic interactions, 242
  - anticholinergic agent-TCA interaction, 254
  - antihypertensive-TCA interaction, 259-260
  - aspirin-TCA interaction, 262
  - baclofen-TCA interaction, 262
  - barbiturate-neuroleptic interactions, 244
  - barbiturate-TCA interaction, 262
  - bupirone-MAOI interaction, 249-250
  - calcium channel blocker-lithium interaction, 269
  - carbamazepine-lithium interaction, 269
  - carbamazepine-neuroleptic interactions, 242-243
  - cimetidine-TCA interaction, 254-256
  - CNS depressant-MAOI interaction, 249
  - digoxin-TCA interaction, 262
  - disulfiram-TCA interaction, 262
  - diuretic-lithium interaction, 264-268
  - guanethidine-neuroleptic interactions, 245
  - hypotensive agent-MAOI interaction, 247
  - hypotensive agent-neuroleptic interactions, 239-242
  - hypotensive agent-TCA interaction, 254
  - L-Dopa-MAOI interaction, 249
  - L-Dopa-neuroleptic interactions, 245
  - lithium interactions, 243-244, 264-272
  - meperidine-MAOI interaction, 249
  - methylidopa-lithium interaction, 269-272
  - monoamine oxidase inhibitor interactions, 245-250, 262
  - neuroleptic interactions, 239-245, 256-258, 269
  - nonsteroidal antiinflammatory drug-lithium interaction, 268
  - physiologic-pharmacokinetic changes with aging and, 236-238
  - propoxyphene-TCA interaction, 262
  - propranolol-TCA interaction, 264
  - sedative agent-neuroleptic interactions, 239
  - sedative agent-TCA interaction, 253-254
  - Sinemet-TCA interaction, 262
  - sympathomimetic agent-MAOI interaction, 247
  - sympathomimetic agent-TCA interaction, 258-259
  - tricyclic antidepressant interactions, 247-248, 253-264
  - tryptophan-MAOI interaction, 248-249
  - tryptophan-TCA interaction, 264
  - types of interactions, 238
  - warfarin-TCA interaction, 264
- Ego autonomy, 384
- creativity and, 387-388
  - neuroanatomic correlation to, 384-385
- Elderly patients, abuse of, 622-623
- affective disorders of. See *Affective disorders, late-onset*.
- bipolar disorder of. See *Bipolar disorder, late-onset*.
- dementia of. See *Demented elderly*.
- depression of. See *Depression, late-onset*.
- drug therapy for, 195-277
- antidepressant. See *Antidepressants, geriatric drug therapy of*.
  - drug interactions of. See *Drug interactions, geriatric psychotropic drug therapy*.
  - lithium. See *Lithium, geriatric drug therapy of*.
  - movement disorders from. See *Drug-induced movement disorders, geriatric*.
  - neuroleptic. See *Neuroleptics, geriatric drug therapy of*.
  - psychiatric disorders from. See *Drug-induced psychiatric disorders, geriatric*.
  - psychoses of. See *Psychoses, late-onset*.
  - schizophrenia of. See *Schizophrenia, late-onset*.
- Electroconvulsive therapy, geriatric therapy of, 10, 92, 207
- Electroencephalography, intracranial mass lesion, 161
- late-onset psychosis, 36
  - degenerative dementia and, 41-42
  - metabolic encephalopathy and, 41
  - silent vascular disease and, 40
  - tumors and, 42
- Emotions, 367-368\*
- definition of, 463\*
  - growth and development of, 461\*
  - hemispheric specialization and, 367-379\*
  - affective disorders and, 368-370\*
  - commissurotomy studies on, 368, 373-374\*
  - creativity and, 374-375\*
  - depression and, 368-370\*
  - hysteria and, 370\*
  - modes of thought and, 377-378\*
  - neuropsychologic studies of, 368-370\*
  - obsessive-compulsive syndrome and, 370\*
  - positive/negative feelings and, 408, 461-472
  - psychopathy and, 370\*

Emotions (*Continued*)

- hemispheric specialization and, schizophrénia and, 368-370\*
  - socioemotional interaction and, 375-378\*
  - variability of transcommissural effects and, 372-374\*
  - historical background on studies of, 367-368
  - neuroanatomic correlation to, amygdaloid complex, 288
  - corpus callosum, 408
  - frontal lobe, 408
  - hippocampus, 288
  - limbic system, 288, 367, 370-372, 461
  - parietal cortex, 461-472
  - reticular activating system, 367
  - positive, 461-472
  - right parietal cortex and, 470-472
  - solace and, 462-470
- Ephedrine, 188
- Esophageal spasm syndrome, anxiety and, 409-410, 413-414

## Fear responses, 377-378

Fluoxetine, 67, 223

Fluvoxamine, 226

Frontal lobes of brain, behavior regulation

and, 384-385

function of, 384-385

managerial capacities and, 416

## Gastrointestinal system, 399-417

anxiety and, 399, 403-417

acute stress experiments of, 403-407

anxiety therapy effect on, 413-414

Crohn's disease and, 411-412

esophageal spasm syndrome and, 409-410, 413-414

functional nausea and vomiting and, 412

inflammatory bowel disease and, 411-412

irritable bowel syndrome and, 408-409, 413

neural and humoral mechanisms correlating, 403-407

nonulcer dyspepsia and, 412

peptic ulcer disease and, 412, 414

physiologic considerations of, 403-407

CNS system regulation of, 400-403

motility of, 401-403

secretion into, 400-401

## Generalized anxiety disorder, diabetes mel-

litus and, 423-429

diagnosis of, 424-427

prognosis for, 428-429

treatment of, 429

diurnal variation of, 448-449

glucose regulation and, 427-428

physiologic responses of, 380-381

monoamine receptor systems and, 318-320

Genetics, late-onset psychosis and, 18-19

violent behavior correlation to, 499-500

Geriatric patients. *See Elderly patients.*

Glycemia, psychologic problems correlated

to disturbances of, 421-422

stress effects on, 420-421

Goldstein-Scheerer Object Sorting Test,

390\*

Haloperidol, 67

violent behavior therapy and, 551, 552

Handwriting, affect expression in, 331\*

alexithymia and. *See Alexithymia, graphologic signs of.\**

cerebral organization for, 331\*

corpus callosotomy effect on, 337-338\*

Hemispheric specialization, affect and, 289\*

alexithymia and, 287, 289-292\*

brain-mind consciousness and, 399-403\*

creativity and. *See Creativity, hemispheric specialization and.\**emotions and. *See Emotions, hemispheric specialization and.\**

handwriting and, 331\*

psychoanalysis and. *See Psychoanalysis, hemispheric specialization and.\**

socioemotional interaction and, 375-378\*

Hippocampus, visceral emotions and, 288\*

Homospatial thinking, 400\*

abstractness and, 452\*

artistic use of, 444-445\*

creativity and, 443-458\*

definition of, 444\*

historical perspectives of, 444\*

realism and, 452\*

Hostage-related violent behavior, 649-664

case studies of, 650-653

debriefing of hostages after, 662-663

management of, 656-660

criminal hostage-takers and, 658-659

emotionally disturbed hostage-takers and, 658

terrorist/political hostage-takers and, 659-660

staff members as hostages in, 660-663

types of hostage-takers and, 654-655

Huntington's disease, characteristics of, 72-73

late-onset, 49, 72-73

types of, 73

Hyperventilation, anxiety and, 467-468

panic disorder and, 468-469

Hypothalamic-pituitary-adrenal axis, agoraphobia and dysfunction of, 339-345

- depression and dysfunction of 339-345
  - immune system and, 354
  - panic disorder and dysfunction of, 337-346, 449-450
  - DST of, 337-338
  - urinary free cortisol abnormalities associated with, 339-346
  - stress and, 335-337, 344
- Hypothalamic-pituitary-thyroid axis, depression and dysfunction of, 450-452
  - panic disorder and dysfunction of, 450-452
- Hysteria, dissociated phenomenon of, 402\*
  - hemispheric brain dysfunction and, 370\*
- Imipramine, geriatric drug therapy of, 217-218
  - cardiovascular effects of, 220-221
  - efficacy of, 223
  - pharmacokinetics of, 217-218
  - plasma levels of, 218
- Immune system, anxiety disorders and, 349-360
  - bereavement and, 350-352
  - central nervous system interaction with, 349-350
  - corticosteroid effects on, 354-356
  - depression and, 352-353
  - growth hormone effects on, 356
  - hypothalamic-pituitary-adrenal axis and, 354
  - sex hormone effects on, 356
  - stress and, 350-358
    - autonomic nervous system effect on, 356-357
    - bereavement, 350-352
    - hormonal effects on, 354-356
    - mediation of, 354-358
    - psychologic responses to, 353-354
    - thyroid hormone effects on, 356
- Inflammatory bowel disease, anxiety and, 411-412
- Interoceptive agnosia, 385
- Intracranial mass lesions, diagnosis of, 161-162
  - differential diagnosis of, 154, 155
  - psychiatric symptoms associated with, 151-163
    - abscesses and, 155
    - adenoma sebaceum and, 156
    - arteriovenous malformations and, 155
    - lipoid proteinosis and, 156
    - non-neoplastic lesions and, 154-156
    - postsurgical, 162
    - prevalence of, 152-154
    - subdural hematomas and, 155
    - tuberculomas and, 155
    - tuberosus sclerosis and, 156
- Irritable bowel syndrome, anxiety and, 408-409, 413
- Isoniazid, mechanism of action of, 173
  - psychiatric side effects of, 173, 175
- Janusian thinking, 389-390, 400\*
- Legal aspects, of rape, 633-634
  - of spouse abuse, 618-619
  - of violence behavior therapy, 665-669
    - confidentiality issues and, 536, 674-675
    - diagnostic issues and, 536
    - duty defined and, 665-666
    - foreseeability factor and, 668-669
    - inpatient injury and, 669, 675-677
    - outpatient injury and, 669-673
    - risk evaluation/management and, 536, 678-679
    - substance abuse and, 674
    - Tarasoff decision and, 667-668
- Limbic system, alexithymia and, 289
- drug-induced sensations and, 343
- emotions and, 288, 367, 370-372, 461
- neocortex compared to, 461
- primitive aspects of, 461
- Lithium, drug interactions of, 243-244
  - calcium-channel blocker, 269
  - carbamazepine, 269
  - diuretic, 264-268
  - methyldopa, 269-272
  - neuroleptic, 269
  - nonsteroidal anti-inflammatory, 268
- geriatric drug therapy of, 127, 207
  - bipolar disorder and, 127
  - dementia and, 207
  - movement disorders induced by, 75-76
  - violent behavior therapy and, 555-557
- Magnetic resonance imaging, intracranial mass lesion, 161
- late-onset psychosis, 37
  - degenerative dementia and, 41-42
  - metabolic encephalopathy and, 41
  - silent vascular disease and, 38, 39
  - tumors and, 42
- Mania, brain tumor-induced, 159
  - late-onset, 17
    - clinical course of, 127
    - diagnosis of, 126-127
    - epidemiology of, 117-118, 121-124
    - etiology of, 124-126
    - genetic factors of, 19
    - organic disorder and, 125-126
    - reaction to loss and, 125
    - signs and symptoms of, 118-121
    - treatment of, 127, 128

- Maprotiline, geriatric drug therapy of, 223-226
- Melancholia, involuntal, 17-18
- Methylphenidate, geriatric drug therapy of, 229
- violent behavior therapy and, 559-560
- Metrizamide, psychiatric side effects of, 189
- Mianserin, geriatric drug therapy of, 223
- MMPI Alexithymia Scale, 355-356\*
- Monoamine oxidase inhibitors, drug interactions with, 245-250
- buspirone, 249-250
  - CNS depressant, 249
  - hypotensive agent, 247
  - L-Dopa, 249
  - meperidine, 249
  - sympathomimetic agent, 247
  - tricyclic antidepressant, 247-248, 262
  - tryptophan, 248-249
- food interactions with, 247
- geriatric drug therapy of, 92, 226-228
- depression and, 226-228
  - efficacy of, 226-228
  - side effects of, 226, 245-247
  - mechanism of action of, 245
- Mood, 135-136
- Mood disorders, brain function and, 133-134
- diagnosis of, 84-85
  - neuropsychological studies of, 51-53
- Movement disorders, age-related changes predisposing to, 62-66
- late-onset psychosis and, 61-76
  - akathisia and, 68
  - Alzheimer's disease and, 73-74
  - benzodiazepine therapy and, 75
  - carbamazepine therapy and, 76
  - catatonia and, 68
  - depression and, 74-75
  - dystonic reactions and, 67-68
  - Huntington's disease and, 72-73
  - L-Dopa dyskinesia and, 71-72
  - lithium therapy and, 75-76
  - medical approach to, 72
  - neuroleptic drug therapy and, 66-70
  - parkinsonism and, 71-72
  - schizophrenia and, 74
  - tardive dyskinesia and, 69-70
  - wandering and, 75
  - Wilson's disease and, 73
- Multi-infarct dementia, late-onset depression and, 105
- late-onset psychosis and, 36, 49
- Neuroleptic malignant syndrome, 68-69, 204-205
- Neuroleptics, drug interactions with, 239-245
- antacid, 245
  - anticholinergic agent, 242
  - barbiturate, 244
  - carbamazepine, 242-243
  - guanethidine, 245
  - hypotensive agent, 239-242
  - L-Dopa, 245
  - lithium, 243-244, 269
  - sedative agent, 239
  - TCA, 256-258
- geriatric drug therapy of, 195-213
- agranulocytosis from, 205
  - akathisia induced by, 68, 203
  - anticholinergic effects of, 205
  - bipolar disorder and, 127
  - cardiovascular effects of, 205
  - catatonia induced by, 68
  - contraindications to, 202-203
  - delirium and, 202
  - dementia and, 199-202
  - dermatologic effects of, 206
  - dosages for, 67
  - dystonic reactions induced by, 67-68
  - extrapyramidal side effects of, 203-205
  - hepatotoxicity from, 205
  - indications for, 66-67
  - movement disorders induced by, 66-70
  - neuroleptic malignant syndrome induced by, 68-69, 204-205
  - ophthalmologic effects of, 206
  - parkinsonism induced by, 68, 203-204
  - schizophrenia and, 10-11
  - sedative effects of, 203
  - sexual dysfunction from, 206
  - side effects of, 70, 203-206
  - sudden death from, 206
  - tardive dyskinesia from, 69-70, 204
  - violent behavior therapy and, 551-554
- Nomifensine, geriatric drug therapy of, 223-226
- Noradrenergic system, anxiety disorders and, 310-316, 318-322, 452-454
- anatomic considerations of, 311-312
  - locus ceruleus regulation correlated to, 312
  - pharmacologic studies of, 313-316, 318-320
  - depression and, 318-320, 452-454
  - gamma-aminobutyric acid effect on, 310-311
  - obsessive-compulsive disorders and, 318-320
  - panic disorders and, 313-315, 318-320, 452-454
- Nortriptyline, geriatric drug therapy of, 218
- cardiovascular effects of, 220-221
  - pharmacokinetics of, 218
  - plasma levels of, 218-219

- Obsessive-compulsive disorders, creativity correlated to, 391-392\*
- depression concurrent with, 448
- hemispheric brain dysfunction and, 370\*
- monoamine receptor systems and, 318-320
- panic disorder concurrent with, 448
- physiologic responses of, 381-382
- Panic disorder, agoraphobia concurrent with, 445
- alcoholism and, 289, 465
- biologic markers/tests of, 449-457, 464-465
- chest pain and, 390-395
- angiographically normal coronary arteries and, 390-391
- atypical or nonanginal, 391-393
- drug therapy for, 393-395
- clonidine studies of, 313-315
- corticotropin-releasing hormone and, 330-332
- cortisol and, dexamethasone suppression test and, 337-338
- urinary free, 339-346
- depression and, 288, 441-461, 465
- agoraphobia and, 445
- biologic markers of, 449-457
- clinical course of, 441-442
- clinical studies of, 444-445
- diurnal variation associated with, 448-449
- hypothalamic-pituitary-adrenal axis in, 449-450
- hypothalamic-pituitary-thyroid axis in, 450-452
- life events affecting, 448
- noradrenergic system in, 452-454
- obsessive-compulsive disorder and, 448
- phenomenology of, 443
- serotonergic system in, 454-455
- sleep and sleep deprivation effects on, 455
- social phobia and, 445-447
- dexamethasone suppression test of, 337-338
- diagnostic criteria for, 312, 313
- diurnal variation of, 448-449
- dizziness associated with, 362, 368
- functional brain mapping studies of, 302-304
- hyperventilation and, 362, 468-469
- hypothalamic-pituitary-adrenal axis activity in, 449-450
- DST as indicator of, 337-338
- urinary free cortisol abnormalities as indicator of, 339-343, 345-346
- hypothalamic-pituitary-thyroid axis in, 450-452
- lactate-induced, 303-304
- monoamine receptor systems and, 313-315, 318-320
- mortality and, 433-440
- cardiovascular, 435-438
- suicidal, 433-435
- noradrenergic system in, 452-454
- obsessive-compulsive disorder concurrent with, 448
- phobia concurrent with, 445-447
- physiologic responses of, 379-380
- positron emission tomography of brain correlated to, 302-303
- selection bias in studies of, 466
- serotonergic system in, 454-455
- sleep and sleep deprivation effects on, 455
- sympathetic nervous system activation and, 312, 313
- variable expressivity of, 465-466
- vestibular system and. See *Vestibular system, panic disorder and dysfunction of.*
- yohimbine studies of, 313-315
- Paraphrenia, 8, 16-17, 34-35
- Parkinson's disease, characteristics of, 71
- depression and, 22, 74-75
- dopaminergic transmission and, 61, 65
- drug therapy for, 169
- dyskinesia from, 71-72
- mechanism of action of, 169
- psychiatric side effects of, 170-172
- neuroleptic-induced, 68, 203-204
- psychosis and, 22, 49
- Peptic ulcer, anxiety and, 412, 414
- Personality, affective dimensions of, 383\*
- cognitive dimensions of, 383\*
- creativity correlated to, 391-393, 443\*
- hemispheric brain dysfunction, effect of, 370\*
- neuropsychology and, 383-384\*
- Phenelzine, geriatric drug therapy of, 218
- cardiovascular effects of, 220-221
- efficacy of, 226-228
- plasma levels of, 219
- Phenylpropanolamine, psychiatric side effects of, 188
- Phobias, alcoholism and, 289
- blood-injury, 378-379
- depression concurrent with, 445-447
- diurnal variation of, 448-449
- ear disease and, 361
- panic disorder concurrent with, 445-447
- peripheral nervous system response of, 378-379
- physiologic responses of, 378-379
- simple, 378
- social, 379
- vertigo and, 361, 366

- Physiognomic Cue Test, 363  
 Pick's disease, late-onset psychosis and, 41, 42  
 Post-traumatic stress disorder, 581-590  
   case studies of, 585-586  
   child abuse and, 602-603  
   drug therapy for, 587-588  
   family therapy for, 587  
   group therapy for, 587  
   historical background of, 581  
   physiologic responses of, 379  
   psychodynamic aspects of, 583-584  
   rape and, 645  
   signs and symptoms of, 582-583  
   theoretical aspects of, 583-584  
   treatment of, 587-588  
 Pseudodementia, definition of, 53  
   late-onset bipolar disorder and, 120  
   late-onset depression and, 90-91, 217  
   neuropsychological studies of, 53-54  
 Psychoanalysis, creativity and, 479-480, 483-485\*  
   hemispheric specialization and, 399, 409-411\*  
   homospatial thinking and, 400\*  
   id, ego, superego considerations of, 400\*  
   information processing and, 407\*  
   Janusian thinking and, 400\*  
   oppositional thinking and, 401\*  
   propositional thinking and, 401\*  
   neuropsychology vs, 399\*  
   positive emotions and, 462\*  
 Psychoses, late-onset, 15-81  
   affective disorders and, 17-18  
   Alzheimer's disease and, 20-21, 36, 41-42, 49  
   brain disease/injury and. See *Brain disease/injury, late-onset psychosis and*  
   cognitive impairment and, 26  
   computerized tomography of. See *Computerized tomography, late-onset psychosis*  
   dementia and. See *Demented elderly, behavioral and psychotic symptoms of*  
   differential diagnosis of, 47-48  
   drug interactions in therapy for. See *Drug interactions, geriatric psychotropic drug therapy*  
   drug-induced. See *Drug-induced psychiatric disorders*  
   electroencephalography of. See *Electroencephalography, late-onset psychosis*  
   female vs male predisposition to, 23-24  
   genetic factors of, 18-19  
   historical review of, 15-18, 33-37  
   Huntington's disease and, 49  
   intracranial mass lesions and. See *Intracranial mass lesion, psychiatric symptoms associated with*  
   magnetic resonance imaging of. See *Magnetic resonance imaging, late-onset psychosis*  
   mechanisms of, 50-51  
   movement disorders and. See *Movement disorders, late-onset psychosis and*  
   neurochemical changes of aging and, 22-23  
   neuroimaging studies of, 33-46  
   neuroleptics for. See *Neuroleptics, geriatric drug therapy of*  
   neurologic disorders associated with, 48-51  
   neuropsychology of, 47-59  
   Parkinson's disease and, 22, 49  
   physical illness predisposing to, 22, 50  
   Pick's disease and, 41, 42  
   premorbid personality and, 23  
   risk factors for, 15-32, 36-37  
   schizophrenia and. See *Schizophrenia, late-onset*  
   sensory impairment and, 19-20  
   social factors of, 25-26  
   wandering and, 75  
   stroke-induced. See *Stroke, psychosis associated with*  
   psychotherapy, for dementia of elderly, 208  
   for rape trauma, 644  
   for spouse abuse, 618  
 Rape, 629-648  
   counseling and psychotherapy for, 644-646  
   crisis intervention for, 645  
   definition of, 631  
   depression from, 639  
   family history of, 638  
   immediate treatment for, 634-635  
   incidence of, 631  
   interview of victim of, 635  
   legal aspects of, 633-634  
   life cycle factors and, 637-638  
   long-term effects of, 638-640  
   low self-esteem from, 639  
   medical history-taking after, 635  
   misconceptions of, 631-633  
   physical examination after, 634-635  
   post-traumatic stress disorder from, 645  
   psychiatric patients as victims of, 642  
   inpatient, 642  
   outpatient, 642  
   psychotherapy and, 643-644  
   self-reports and, 643  
   psychodynamics of, 640-641

- psychopathology and, 641-642  
 rapist profile and, 633  
 relationship problems due to, 639-640  
 risk factors predisposing to, 631  
 sexual dysfunction from, 639  
 silent reaction to, 638  
 submissive response to, 633  
 trauma syndrome of, 635-639  
 Reticular activating system, emotions and, 367\*  
 Rorschach Test, alexithymia indices of, 358-359\*  
  
 Schalling-Sifneos Personality Scale, 354-355\*  
 Schizophrenia, anxiety disorders and, 289  
   brain damage/dysfunction and, corpus callosum enlargement and, 407\*  
   hemispheric, 368, 369, 390\*  
   tumor-induced, 157  
 catatonic, 74  
 clonidine studies of, 313  
 creativity correlated to, 389-391\*  
 depression and, 286  
 dopaminergic transmission in, 61, 64-65  
 late-onset, 1-12  
 Alzheimer's disease and, 20-21  
   brain disease/injury and, 20, 36-37  
   clinical course of, 9, 11  
   clinical studies of, 1-8, 11-12  
   construct validity of, 2  
   deafness and, 19-20  
   descriptive validity of, 2, 8  
   diagnostic criteria for, 2-3, 6, 11  
   differential diagnosis of, 11  
   early-onset vs., 6-8  
   electroconvulsive therapy for, 10  
   face validity of, 2  
   female vs male predisposition for, 23-24  
   genetic factors of, 18  
   historical review of, 15-17, 33-37  
   neurochemical changes of aging and, 22-23  
   neuroleptic drug therapy for, 10-11  
   neuropsychological studies of, 54-56  
   paraphrenia and, 8, 16-17, 34-35  
   patient sources for studies of, 3-4, 6  
   physical diseases associated with, 22  
   predictive validity of, 2, 8  
   premorbid personality predisposing to, 23  
   prognosis for, 9  
   psychosocial therapy for, 11  
   results of studies of, 4-8  
   review of literature on, 8-11  
   sensory impairment and, 19-20  
   social factors contributing to, 25-26  
   symptoms of, 8-9, 11  
   treatment of, 10-11  
   visual loss and, 20  
 Sedatives and hypnotics, drug interactions with, 239, 253-254  
   mechanism of action of, 183  
   psychiatric side effects of, 183, 187  
 Senile chorea, 66  
 Senile tremor, 66  
 Serotonergic system, anxiety disorders and, 310-311, 316-322, 454-455  
   hormonal fluctuations correlated to, 317-318  
   pharmacologic studies of, 316-320  
   depression and, 318-320, 454-455  
   function of, 316  
   gamma-aminobutyric acid effect on, 310-311  
   obsessive-compulsive disorders and, 318-320  
   panic disorders and, 318-320, 454-455  
   violent behavior and, 501-503, 560  
 Sexual abuse, children as victims of. See *Child abuse, sexual abuse.*  
   definition of, 630  
   incest. See *Child abuse, sexual abuse.*  
   incidence of, 631  
   rape. See *Rape.*  
 Short Imaginal Processes Inventory, 363  
 Sleep and sleep deprivation, depression and, 455  
   panic disorder and, 455  
 Solace, 462\*  
   absence of, 464\*  
     alexithymia and, 470\*  
     personality disorder and, 470\*  
   alexithymia and, 470\*  
   awe and, 463\*  
   bliss and, 463\*  
   case presentations of, 467-470\*  
   derivatives of, 463-464\*  
   elation and, 463\*  
   language capacity correlated to, 466\*  
   noninstinctual nature of, 464-465\*  
   nurturing maternal presence associated with, 466\*  
   physical effects of, 464-465\*  
   physical site of, lack of, 465\*  
   self-sacrificing in relation to, 464\*  
   sexual feelings combined with, 463\*  
 Spouse abuse, 611-620  
   alcohol abuse and, 620  
   case studies of, 615-616  
   definition of, 612  
   diagnosis of, 613  
   emotional abuse, 616-617  
   epidemiology of, 612  
   etiology of, 613-614  
   historical background of, 611-612  
   law enforcement and, 618-619

- Spouse abuse (*Continued*)  
 learned behaviors and, 615  
 prevention of, 624-625  
 psychological abuse, 616-617  
 psychotherapy for, 618  
 risk factors predisposing to, 620  
 sex role socialization in, 613-615  
 socioeconomic factors in, 620  
 treatment for, 617-620, 624  
   for men, 619-620  
   for women, 617-619  
 verbal abuse, 616-617
- Steroids, mechanism of action of, 179  
 psychiatric side effects of, 179, 180  
 violent behavior therapy and, 561
- Stimulants, geriatric drug therapy of, 188, 228-229
- Stroke, delusions associated with, 143-145  
 depression associated with, 22, 133-149  
   bilateral lesion location correlated to, 140-141  
   biologic markers of, 142  
   clinical course of, 141-142  
   cortical vs subcortical lesion location correlated to, 141  
   epidemiology of, 137-139  
   hemispheric lesion location correlated to, 139-140  
   severity of, 141  
   treatment of, 142-143  
 epidemiology of, 134  
 mood disorder associated with, 133-134  
 psychosis associated with, 20, 133-149  
   delusional, 143-145  
   neuroimaging studies of, 38-40  
   neuropsychologic studies of, 49-50  
 syndromes associated with, 135
- Symbollexia, 307, 372\*  
 commissurotomy effect on, 307-308\*  
 corpus callosum in, role of, 307-308\*  
 inner vision process technique and, 430\*
- Tardive dyskinesia, 61  
 aging and, 69-70  
 neuroleptic-induced, 67, 69-70, 204  
 treatment of, 70
- Tardive syndromes, 70
- Thematic Apperception Test, 358\*
- Thioridazine, extrapyramidal side effects of, 67  
 violent behavior therapy and, 553
- Thiothixene, extrapyramidal side effects of, 67
- Thyroid replacement therapy, psychiatric side effects of, 188-189
- Toronto Alexithymia Scale, 356-358, 360-363\*
- Tranylcypromine, geriatric drug therapy of, 226-228
- Trazadone, geriatric drug therapy of, 218  
 cardiovascular effects of, 220  
 dementia and, 207  
 efficacy of, 223
- Tremor, senile, 66
- Tricyclic antidepressants, drug interactions with, 247-248  
 antiarrhythmic, 260  
 anticholinergic agent, 254  
 antihypertensive drug, 259-260  
 aspirin, 262  
 baclofen, 262  
 barbiturate, 262  
 cimetidine, 254-256  
 digoxin, 262  
 disulfiram, 262  
 hypotensive agent, 254  
 monoamine oxidase inhibitor, 262  
 neuroleptic, 256-258  
 propoxyphene, 262  
 propranolol, 264  
 sedative agent, 253-254  
 Sinemet, 262  
 sympathomimetic drug, 258-259  
 tryptophan, 264  
 warfarin, 264  
 geriatric drug therapy of, 217-226  
 cardiovascular effects of, 220-221  
 pharmacokinetics of, 217-218  
 side effects of, 220-221  
 violent behavior therapy and, 561
- Trifluoperazine, extrapyramidal side effects of, 67
- Unipolar disorder, late-onset, epidemiology of, 85-87  
 neuropsychological studies of, 51-53
- Verbalizer-Visualizer Questionnaire, 363\*
- Vertigo, agoraphobia and, 361, 366  
 anxiety disorders and, 361-362, 366  
 panic disorders and, 362, 366-367  
 phobias and, 361, 366  
 psychosomatic effects on, 367-369
- Vestibular system, 361-374  
 agoraphobia and dysfunction of, 361, 363, 366  
 anxiety disorders and dysfunction of, 361-374  
 arousal and attention level effect on, 368-369  
 behavioral effects on, 368-369  
 compensation for injury to, 365  
 emotional problems associated with dysfunction of, 366  
 habitation effect on, 368  
 hyperventilation effect on, 369



- panic disorder and dysfunction of, 361-374  
 nonspecificity of association of, 369-370  
 prevalence of, 362, 363  
 psychosomatic effects on, 367-369  
 somatopsychic model of, 364-367  
 symptoms related to, 366-367  
 tests of, 362-364  
 pseudoagoraphobia and dysfunction of, 366  
 psychologic effects on, 368-369  
 psychosomatic effects on, 367-369  
 Viloxazine, geriatric drug therapy of, 22c  
 Violent behavior, agency relationship of treating physician to patient of, 536-537  
 alcohol use associated with, 504-505, 561, 674  
 biologic aspects of, 499-509  
 clinical evaluation of, 527-537  
 consultations in, 532  
 differential diagnosis from, 532-533  
 family history in, 530  
 interview in, 528-530  
 laboratory tests in, 532  
 medical history in, 530  
 mental status examination in, 530-531  
 physical examination in, 531  
 psychiatric history in, 529-530  
 psychological tests in, 532  
 risk evaluation from, 533-536  
 consultations on, 532  
 cultural aspects of, 512-518  
   regional cultures of violence and, 515-517  
   societal cultures of violence and, 517-518  
   subcultures of violence and, 512-514  
 demographic correlates of, 511-512  
 differential diagnosis of, 532-533, 540-541  
 drug abuse associated with, 504-506, 561, 674  
 drug therapy for, 551-567  
   alprazolam, 557  
   amphetamines, 559-561  
   anticholinergic, 561  
   anticonvulsant, 554-555  
   baclofen, 561  
   barbiturate, 552, 554  
   benzodiazepine, 552-553, 557-558  
   beta-adrenergic blocker, 558-559  
   carbamazepine, 554-555, 559  
   chloridiazepoxide, 552, 557-558  
   chlorpromazine, 551, 552  
   chlorprothixene, 553  
   clonazepam, 557  
   deanol, 561  
   dextedrine, 559-560  
   diazepam, 552, 557-558  
   diphenylhydantoin, 554, 559-560  
   dosage guidelines for, 551-552  
   ethosuximide, 554  
   fenfluramine, 561  
   fluphenazine, 552, 553  
   haloperidol, 551, 552  
   historical background of, 551  
   lithium, 555-557  
   lorazepam, 552-553  
   medroxyprogesterone acetate, 561  
   mesoridazine, 553  
   methadone, 561  
   methodologic limitations of studies of, 562  
   methylphenidate, 559-560  
   metoprolol, 559  
   neuroleptic, 551-554  
   perphenazine, 553  
   pindolol, 559  
   primidone, 554  
   propranolol, 558-559  
   psychostimulant, 559-560  
   serotonin uptake inhibitor, 560  
   sodium amytal, 551-552  
   thioridazine, 553  
   tricyclic antidepressant, 561  
   trihexyphenidyl, 561  
   tryptophan supplementation and, 560  
   verapamil, 561  
 emergency treatment of, 539-549  
   defensive actions in, 539-540  
   differential diagnosis in, 540-541  
   environmental analysis in, 541-542  
   prevention of, 542-543  
   protective posture in, 539-540  
   seclusion and restraint procedures for, 543-549  
   verbal interaction in, 541-543  
 family history of, 530  
 genetic factors correlating to, 499-500  
 geographic correlates of, 512  
 hormonal imbalances and, 500-501  
 hostage-related. *See Hostage-related violent behavior.*  
 interview of patient with, 528-530  
 laboratory tests for evaluation of, 532  
 legal implications of patient care with. *See Legal aspects, of violence behavior therapy.*  
 medical history of, 530  
 menstrual cycle and, 501  
 mental status examination of, 530-531  
 minimal brain dysfunction and, 503, 560  
 neurotransmitter activity and, 501-503  
 organic disorders associated with, 531  
 physical examination for evaluation of, 531  
 prediction of, 533-536  
 psychiatric disorders associated with, 503-504  
 psychiatric history of, 529-530  
 psychological tests of, 532

Violent behavior (*Continued*)rape and. See *Rape*.

risk evaluation for, 533-536

characteristics of patient in, analysis of, 534

danger assessment for interviewer in, 535-536

environmental setting and, 534

time limits and, 534

seclusion and restraint of patient with, 543-549

contraindications to, 544-545

implementation of procedures for, 545-546

indications for, 544

monitoring of, 547-548

national standards for, 543-544

patient care during, 548-549

physician's responsibility in, 546-547

termination of, 549

seizure activity and, 503-504, 554-

555

sexual abuse and. See *Sexual abuse*.

socioeconomic factors correlated to, 518-

522

ascriptive inequality and, 521-522

economic inequality and, 520

opportunity inequality and, 521-522

poverty levels and, 519-520

treatment of, behavioral therapy. See *Behavioral therapy, for violent behavior*.

drug therapy, 551-567

emergency situation, 539-549

victims of, 512

children as. See *Child abuse*.

demographic correlates of, 512

elderly population as, 622-623

handicapped individuals as, 624

parents as, 623

post-traumatic stress disorder of. See *Post-traumatic stress disorder*.

siblings as, 623

spouses as. See *Spouse abuse*.

Vividness of Visual Imagery Questionnaire, 443-444\*

Wandering behavior, psychosis in elderly and, 75

Wilson's disease, late-onset, 73

